SynSolve delivers a paradigm shift in gas liquid processes by first dissolving gas at high pressure and then reacting the dissolved gas to form products. This not only renders the process scalable, but it also significantly reduces the footprint of operation, lowering solvent use, energy and raw material requirements. The lower stoichiometry requirements of chemical transformations done by the dissolving gas technology is also expected to lead to lower by-product formation and higher yields. A win-win for both industry and the planet. AMT and CPTP have teamed up with the University of Leeds to develop low energy gas dissolution technology based on bubble trains and use the dissolver in CPTP’s lab to develop new low-cost medicine synthesis routes. CPTP is currently developing a pipeline of APIs and in several cases dissolved gas reactions the of key intermediates will not only reduce the cost of the final product. In addition, it will introduce safe operating procedures and lead to green responsible processes. One of the products will be scaled up to 1 kg to demonstrate the performance of the new dissolved gas reactor technology and its impact in manufacturing drugs like omeprazole, an off patent gastrointestinal drug at low cost. Our vision is to replace all inefficient, high risk large volume batch hydrogenations into safe, low inventory and atom efficient continuous flow processes, akin to the Chinese change-over to continuous nitration.